CD274 and non-small cell lung carcinoma: Immune checkpoint therapy, particularly anti-programmed cell death receptor-1 (PD-1)/anti-programmed cell death ligand-1 (PD-L1) antibody, is a novel cancer therapy and has become the standard therapy for a variety of tumors, including non-small cell lung cancer (NSCLC)6–8.